Li K, Yu J J, Hung C Y, Lehmann P F, Cole G T
Department of Microbiology and Immunology, Medical College of Ohio, Toledo, Ohio 43614-5806, USA.
Infect Immun. 2001 May;69(5):2878-87. doi: 10.1128/IAI.69.5.2878-2887.2001.
Coccidioides immitis antigens which stimulate a T helper cell 1 (Th1) pathway of host immune response are considered to be essential components of a vaccine against coccidioidomycosis. Recombinant urease (rURE) and recombinant heat shock protein 60 (rHSP60) of C. immitis were expressed in Escherichia coli and tested as vaccine candidates in BALB/c mice. A synthetic oligodeoxynucleotide which contained unmethylated CpG dinucleotides and was previously shown to enhance a murine Th1 response was used as an immunoadjuvant. T cells isolated from the spleens and lymph nodes of the rURE- and rHSP60-immune mice showed in vitro proliferative responses to the respective recombinant protein, but only those T lymphocytes from rURE-immunized mice revealed markedly elevated levels of expression of selected Th1-type cytokine genes. BALB/c mice immunized subcutaneously with rURE and subsequently challenged by the intraperitoneal (i.p.) route with a lethal inoculum of C. immitis arthroconidia demonstrated a significant reduction in the level of C. immitis infection compared to control animals. rHSP60 was much less effective as a protective antigen. Evaluation of cytokine gene expression in lung tissue and levels of recombinant urease-specific immunoglobulins (immunoglobulin G1 [IgG1] versus IgG2a) in murine sera at 12 days after challenge provided additional evidence that immunization with rURE stimulated a Th1 response to the pathogen. Urease was further evaluated by expression of the URE gene in a mammalian plasmid vector (pSecTag2A.URE) which was used to immunize mice by the intradermal route. In this case, 82% of the vector construct-immunized animals survived more than 40 days after i.p. infection, compared to only 10% of the mice immunized with the vector alone. In addition, 87% of the pSecTag2A.URE-immunized survivors had sterile lungs and spleens. These data support the need for further evaluation of the C. immitis urease as a candidate vaccine against coccidioidomycosis.
刺激宿主免疫反应的T辅助细胞1(Th1)途径的粗球孢子菌抗原被认为是抗球孢子菌病疫苗的重要组成部分。粗球孢子菌的重组脲酶(rURE)和重组热休克蛋白60(rHSP60)在大肠杆菌中表达,并作为候选疫苗在BALB/c小鼠中进行测试。一种含有未甲基化CpG二核苷酸且先前已证明可增强小鼠Th1反应的合成寡脱氧核苷酸被用作免疫佐剂。从rURE免疫和rHSP60免疫小鼠的脾脏和淋巴结中分离出的T细胞对各自的重组蛋白表现出体外增殖反应,但只有来自rURE免疫小鼠的那些T淋巴细胞显示出所选Th1型细胞因子基因的表达水平明显升高。用rURE皮下免疫的BALB/c小鼠随后经腹腔(i.p.)途径用致死剂量的粗球孢子菌关节孢子攻击,与对照动物相比,其粗球孢子菌感染水平显著降低。rHSP60作为保护性抗原的效果要差得多。在攻击后12天评估肺组织中的细胞因子基因表达以及小鼠血清中重组脲酶特异性免疫球蛋白(免疫球蛋白G1 [IgG1]与IgG2a)的水平,提供了额外的证据表明用rURE免疫可刺激对病原体的Th1反应。通过在哺乳动物质粒载体(pSecTag2A.URE)中表达URE基因进一步评估脲酶,该载体用于通过皮内途径免疫小鼠。在这种情况下,82%的载体构建体免疫动物在腹腔感染后存活超过40天,而仅用载体免疫的小鼠中这一比例为10%。此外,87%的pSecTag2A.URE免疫存活者的肺和脾脏无菌。这些数据支持进一步评估粗球孢子菌脲酶作为抗球孢子菌病候选疫苗的必要性。